TY - JOUR
T1 - Pros and cons of different therapeutic antibody formats for recombinant antivenom development
AU - Laustsen, Andreas H.
AU - Gutiérrez, José María
AU - Knudsen, Cecilie
AU - Johansen, Kristoffer H.
AU - Bermúdez-Méndez, Erick
AU - Cerni, Felipe A.
AU - Jürgensen, Jonas A.
AU - Jensen, Line Ledsgaard
AU - Martos Esteban, Andrea
AU - Øhlenschlæger, Mia
AU - Pus, Urska
AU - Andersen, Mikael R.
AU - Lomonte, Bruno
AU - Engmark, Mikael
AU - Pucca, Manuela B.
PY - 2018
Y1 - 2018
N2 - Antibody technologies are
being increasingly applied in the field of toxinology. Fuelled by the many
advances in immunology, synthetic biology, and antibody research, different
approaches and antibody formats are being investigated for the ability to
neutralize animal toxins. These different molecular formats each have their own
therapeutic characteristics. In this review, we provide an overview of the
advances made in the development of toxin-targeting antibodies, and discuss the
benefits and drawbacks of different antibody formats in relation to their
ability to neutralize toxins, pharmacokinetic features, propensity to cause
adverse reactions, formulation, and expression for research and development
(R&D) purposes and large-scale manufacturing. A research trend seems to be
emerging towards the use of human antibody formats as well as camelid
heavy-domain antibody fragments due to their compatibility with the human
immune system, beneficial therapeutic properties, and the ability to
manufacture these molecules cost-effectively.
AB - Antibody technologies are
being increasingly applied in the field of toxinology. Fuelled by the many
advances in immunology, synthetic biology, and antibody research, different
approaches and antibody formats are being investigated for the ability to
neutralize animal toxins. These different molecular formats each have their own
therapeutic characteristics. In this review, we provide an overview of the
advances made in the development of toxin-targeting antibodies, and discuss the
benefits and drawbacks of different antibody formats in relation to their
ability to neutralize toxins, pharmacokinetic features, propensity to cause
adverse reactions, formulation, and expression for research and development
(R&D) purposes and large-scale manufacturing. A research trend seems to be
emerging towards the use of human antibody formats as well as camelid
heavy-domain antibody fragments due to their compatibility with the human
immune system, beneficial therapeutic properties, and the ability to
manufacture these molecules cost-effectively.
KW - Antivenom
KW - Venom
KW - Recombinant antivenom
KW - Antibodies
KW - Snakebite
KW - Scorpion sting
KW - Spider bite
KW - Animal envenoming
KW - Pharmacokinetics
KW - Pharmacodynamics
KW - Immunogenicity
KW - Venom neutralization
KW - Antibody expression
KW - Antivenom design
KW - Adverse reactions
KW - Neglected tropical diseases
KW - Biotechnology
U2 - 10.1016/j.toxicon.2018.03.004
DO - 10.1016/j.toxicon.2018.03.004
M3 - Journal article
C2 - 29534892
SN - 0041-0101
VL - 146
SP - 151
EP - 175
JO - Toxicon
JF - Toxicon
ER -
